NCT03778931 2025-09-15EMERALDStemline Therapeutics, Inc.Phase 3 Completed478 enrolled 16 charts 1 FDA
NCT04975308 2025-07-11EMBER-3Eli Lilly and CompanyPhase 3 Active not recruiting874 enrolled 29 charts 1 FDA